Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis.

Lunde CS, Stebbins EE, Jumani RS, Hasan MM, Miller P, Barlow J, Freund YR, Berry P, Stefanakis R, Gut J, Rosenthal PJ, Love MS, McNamara CW, Easom E, Plattner JJ, Jacobs RT, Huston CD.

Nat Commun. 2019 Jun 27;10(1):2816. doi: 10.1038/s41467-019-10687-y.

2.

A suite of phenotypic assays to ensure pipeline diversity when prioritizing drug-like Cryptosporidium growth inhibitors.

Jumani RS, Hasan MM, Stebbins EE, Donnelly L, Miller P, Klopfer C, Bessoff K, Teixeira JE, Love MS, McNamara CW, Huston CD.

Nat Commun. 2019 Apr 23;10(1):1862. doi: 10.1038/s41467-019-09880-w.

3.

Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis.

Baragaña B, Forte B, Choi R, Nakazawa Hewitt S, Bueren-Calabuig JA, Pisco JP, Peet C, Dranow DM, Robinson DA, Jansen C, Norcross NR, Vinayak S, Anderson M, Brooks CF, Cooper CA, Damerow S, Delves M, Dowers K, Duffy J, Edwards TE, Hallyburton I, Horst BG, Hulverson MA, Ferguson L, Jiménez-Díaz MB, Jumani RS, Lorimer DD, Love MS, Maher S, Matthews H, McNamara CW, Miller P, O'Neill S, Ojo KK, Osuna-Cabello M, Pinto E, Post J, Riley J, Rottmann M, Sanz LM, Scullion P, Sharma A, Shepherd SM, Shishikura Y, Simeons FRC, Stebbins EE, Stojanovski L, Straschil U, Tamaki FK, Tamjar J, Torrie LS, Vantaux A, Witkowski B, Wittlin S, Yogavel M, Zuccotto F, Angulo-Barturen I, Sinden R, Baum J, Gamo FJ, Mäser P, Kyle DE, Winzeler EA, Myler PJ, Wyatt PG, Floyd D, Matthews D, Sharma A, Striepen B, Huston CD, Gray DW, Fairlamb AH, Pisliakov AV, Walpole C, Read KD, Van Voorhis WC, Gilbert IH.

Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):7015-7020. doi: 10.1073/pnas.1814685116. Epub 2019 Mar 20.

4.

Optimization of Methionyl tRNA-Synthetase Inhibitors for Treatment of Cryptosporidium Infection.

Buckner FS, Ranade RM, Gillespie JR, Shibata S, Hulverson MA, Zhang Z, Huang W, Choi R, Verlinde CLMJ, Hol WGJ, Ochida A, Akao Y, Choy RKM, Van Voorhis WC, Arnold SLM, Jumani RS, Huston CD, Fan E.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02061-18. doi: 10.1128/AAC.02061-18. Print 2019 Apr.

PMID:
30745384
5.

A Novel Piperazine-Based Drug Lead for Cryptosporidiosis from the Medicines for Malaria Venture Open-Access Malaria Box.

Jumani RS, Bessoff K, Love MS, Miller P, Stebbins EE, Teixeira JE, Campbell MA, Meyers MJ, Zambriski JA, Nunez V, Woods AK, McNamara CW, Huston CD.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e01505-17. doi: 10.1128/AAC.01505-17. Print 2018 Apr.

6.

Clinical and microbiologic efficacy of the piperazine-based drug lead MMV665917 in the dairy calf cryptosporidiosis model.

Stebbins E, Jumani RS, Klopfer C, Barlow J, Miller P, Campbell MA, Meyers MJ, Griggs DW, Huston CD.

PLoS Negl Trop Dis. 2018 Jan 8;12(1):e0006183. doi: 10.1371/journal.pntd.0006183. eCollection 2018 Jan.

7.

Targeting Prolyl-tRNA Synthetase to Accelerate Drug Discovery against Malaria, Leishmaniasis, Toxoplasmosis, Cryptosporidiosis, and Coccidiosis.

Jain V, Yogavel M, Kikuchi H, Oshima Y, Hariguchi N, Matsumoto M, Goel P, Touquet B, Jumani RS, Tacchini-Cottier F, Harlos K, Huston CD, Hakimi MA, Sharma A.

Structure. 2017 Oct 3;25(10):1495-1505.e6. doi: 10.1016/j.str.2017.07.015. Epub 2017 Aug 31.

8.

Discovery and structure activity relationship of the first potent cryptosporidium FIKK kinase inhibitor.

Osman KT, Ye J, Shi Z, Toker C, Lovato D, Jumani RS, Zuercher W, Huston CD, Edwards AM, Lautens M, Santhakumar V, Hui R.

Bioorg Med Chem. 2017 Mar 1;25(5):1672-1680. doi: 10.1016/j.bmc.2017.01.036. Epub 2017 Jan 24.

PMID:
28162900
9.

A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis.

Love MS, Beasley FC, Jumani RS, Wright TM, Chatterjee AK, Huston CD, Schultz PG, McNamara CW.

PLoS Negl Trop Dis. 2017 Feb 3;11(2):e0005373. doi: 10.1371/journal.pntd.0005373. eCollection 2017 Feb.

10.

The Secreted Protein Rv1860 of Mycobacterium tuberculosis Stimulates Human Polyfunctional CD8+ T Cells.

Satchidanandam V, Kumar N, Biswas S, Jumani RS, Jain C, Rani R, Aggarwal B, Singh J, Kotnur MR, Sridharan A.

Clin Vaccine Immunol. 2016 Apr 4;23(4):282-93. doi: 10.1128/CVI.00554-15. Print 2016 Apr.

11.

The glycosylated Rv1860 protein of Mycobacterium tuberculosis inhibits dendritic cell mediated TH1 and TH17 polarization of T cells and abrogates protective immunity conferred by BCG.

Satchidanandam V, Kumar N, Jumani RS, Challu V, Elangovan S, Khan NA.

PLoS Pathog. 2014 Jun 12;10(6):e1004176. doi: 10.1371/journal.ppat.1004176. eCollection 2014 Jun. Erratum in: PLoS Pathog. 2014 Aug;10(8):e1004352.

12.

Identification of Cryptosporidium parvum active chemical series by Repurposing the open access malaria box.

Bessoff K, Spangenberg T, Foderaro JE, Jumani RS, Ward GE, Huston CD.

Antimicrob Agents Chemother. 2014 May;58(5):2731-9. doi: 10.1128/AAC.02641-13. Epub 2014 Feb 24.

Supplemental Content

Loading ...
Support Center